I
316.43
-1.88 (-0.59%)
| Previous Close | 318.30 |
| Open | 317.97 |
| Volume | 85,053 |
| Avg. Volume (3M) | 626,893 |
| Market Cap | 22,273,957,888 |
| Price / Earnings (TTM) | 96.47 |
| Price / Earnings (Forward) | 54.95 |
| Price / Sales | 9.57 |
| Price / Book | 15.03 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | 18.29% |
| Operating Margin (TTM) | 15.61% |
| Diluted EPS (TTM) | 5.54 |
| Quarterly Revenue Growth (YOY) | 28.80% |
| Quarterly Earnings Growth (YOY) | -31.30% |
| Total Debt/Equity (MRQ) | 131.40% |
| Current Ratio (MRQ) | 4.47 |
| Operating Cash Flow (TTM) | 406.50 M |
| Levered Free Cash Flow (TTM) | 84.25 M |
| Return on Assets (TTM) | 6.94% |
| Return on Equity (TTM) | 37.92% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Insulet Corporation | Bullish | Bullish |
AIStockmoo Score
-0.5
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -2.0 |
| Average | -0.50 |
|
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.29% |
| % Held by Institutions | 102.56% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 399.00 (Canaccord Genuity, 26.10%) | Buy |
| Median | 357.50 (12.98%) | |
| Low | 300.00 (Barclays, -5.19%) | Hold |
| Average | 355.67 (12.40%) | |
| Total | 5 Buy, 1 Hold | |
| Avg. Price @ Call | 320.14 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stifel | 21 Oct 2025 | 370.00 (16.93%) | Buy | 318.59 |
| Canaccord Genuity | 29 Sep 2025 | 399.00 (26.10%) | Buy | 310.62 |
| 08 Aug 2025 | 353.00 (11.56%) | Buy | 307.10 | |
| Oppenheimer | 08 Sep 2025 | 365.00 (15.35%) | Buy | 349.56 |
| Barclays | 21 Aug 2025 | 300.00 (-5.19%) | Hold | 327.85 |
| RBC Capital | 08 Aug 2025 | 350.00 (10.61%) | Buy | 307.10 |
| Wells Fargo | 08 Aug 2025 | 350.00 (10.61%) | Buy | 307.10 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 10 Oct 2025 | Announcement | Insulet to Host Investor Day on November 20, 2025 |
| 18 Sep 2025 | Announcement | Insulet and Pantone® Partner to Launch Omnipod® Mango in Vibrant New Palette |
| 16 Sep 2025 | Announcement | Insulet Announces CFO Transition |
| 25 Aug 2025 | Announcement | Insulet Elevates Eric Benjamin to Chief Operating Officer |
| 19 Aug 2025 | Announcement | Insulet to Participate in Upcoming Investor Conferences |
| 07 Aug 2025 | Announcement | Insulet Reports Second Quarter 2025 Revenue Increase of 32.9% Year-Over-Year (31.3% Constant Currency¹) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |